Eikon Therapeutics joins a growing number of startups researching how proteins move in cells as a basis for drug discovery. Roger Perlmutter joins Eikon as its CEO just four months after he retired as Merck’s top research executive.
New research by the Cancer Research Institute puts the number of industry-wide combination trials at 1,105.
In this episode hear how improving benefit verification, prior authorizations, and patient affordability with smart integrations and real-time eligibility can streamline healthcare workflows.
Chrono Therapeutics will use the funding to support clinical trials of the wearable device in the U.S. and Europe to wean smokers off cigarettes using timed delivery of nicotine.